Johnson & Johnson (NYSE:JNJ) – Should Johnson & Johnson Bet On An Antipsychotic Acquisition?

November 18, 2013 at 09:12 AM EST

[at Seeking Alpha] – Last week marked the end of a two-year case involving Johnson & Johnson’s ( JNJ ) subsidiary Janssen Pharmaceuticals and the U.S. government. The case alleged that Janssen marketed . . . → Read More: Johnson & Johnson (NYSE:JNJ) – Should Johnson & Johnson Bet On An Antipsychotic Acquisition? Similar posts: Stock Update: NIKE Inc. (NYSE:NKE) – Under Armour goes after activity tracking in a big way with acquisition of MapMyFitness Johnson & Johnson (NYSE:JNJ) – Is Johnson & Johnson a Buy at These Prices? Johnson & Johnson (NYSE:JNJ) | Johnson & Johnson Wants Extra Strength Assurance from Amazon

Johnson & Johnson (NYSE:JNJ) [at Seeking Alpha] – Last week marked the end of a two-year case involving Johnson & Johnson’s ( JNJ ) subsidiary Janssen Pharmaceuticals and the U.S. government. The case alleged that Janssen marketed antipsychotics, including …
Read more on … [visit site to read more]